ERBB2 and glioblastoma: To develop a clinically viable CPR/CART, we studied the impact of CPR on the phenotype of CART derived from patients with glioblastoma (GBM), a profoundly immune-suppressive tumor (28–31), and assessed their effector function against autologous tumor cells with variable HER2 and PD-L1 expressions.